ScholarIQanswers from OpenAlex & ORCID
Wěi Li
ResearcherPublications, citations & collaboration network
Wěi Li is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Wěi Li have?
ScholarIQindexed works
Wěi Li has 2,221 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Wěi Li have?
ScholarIQcitation count
Wěi Li has 74,732 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Wěi Li?
ScholarIQh-index
Wěi Li has an h-index of 109 in OpenAlex.
What is the i10-index of Wěi Li?
ScholarIQi10-index
Wěi Li has an i10-index of 1,048 in OpenAlex.
What is the ORCID of Wěi Li?
ScholarIQorcid
The ORCID for Wěi Li is on the source record.
What is the OpenAlex record for Wěi Li?
ScholarIQopenalex
The OpenAlex for Wěi Li is on the source record.
What are the most-cited papers on Wěi Li?
ScholarIQmost cited works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen‐Zhao Zhong, Qun Wang, Weimin Mao, Lin Xu, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Hong‐Hong Yan, Xue‐Ning Yang, Qing Zhou, Yi‐Long Wu, Yi‐Long Wu, Qun Wang, Weimin Mao, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Zhi Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Siyu Wang, Jian Hu, Wei Liu, Wěi Li, Jianhua Shi
Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis
Xiaobo Xia, Madeleine E. Lemieux, Wěi Li, Jason S. Carroll, Myles Brown, X. Shirley Liu, Andrew L. Kung
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wěi Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou